Antidepressant prescribing patterns and patient-reported adverse effects: a cross-sectional study from Pakistan.

IF 5.8 3区 医学 Q1 PSYCHIATRY
Sohail Riaz, Fazli Khuda, Abuzar Khan, Asif Jan, Samir Ibenmoussa, Ghallab Alotaibi, Syed Shaukat Ali, Basmah Abdulaziz Albabtain
{"title":"Antidepressant prescribing patterns and patient-reported adverse effects: a cross-sectional study from Pakistan.","authors":"Sohail Riaz, Fazli Khuda, Abuzar Khan, Asif Jan, Samir Ibenmoussa, Ghallab Alotaibi, Syed Shaukat Ali, Basmah Abdulaziz Albabtain","doi":"10.1186/s12991-026-00644-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Antidepressant prescribing practices and Adverse-effect profiles are poorly characterised in Pakistan, highlighting the need for systematic evaluation. This study aimed to assess prescribing patterns, validate the Urdu version of the Antidepressant Side-Effect Checklist (U-ASEC), and document patient-reported adverse effects.</p><p><strong>Methods: </strong>A cross-sectional questionnaire-based study was conducted at two psychiatry clinics in Lahore and Rawalpindi. All adult patients diagnosed with MDD according to the DSM-5-TR were invited to participate. Sampling was done through a convenient method. The Urdu-translated Antidepressant Side-Effect Checklist (U-ASEC) was developed through forward-back translation, expert panel review and pilot testing, and its psychometric properties such as internal consistency, construct validity were examined. Descriptive statistics were used to summarize demographic and clinical characteristics. Differences in adverse-effect scores across demographic and clinical groups were assessed with Kruskal-Wallis tests followed by Dunn's test with Bonferroni adjustment. Multivariable logistic regression models were fitted for each adverse-effect item to explore associations with antidepressant classes, adjusting for age, sex, tobacco use, comorbidity and duration of MDD. Multicollinearity was checked using variance inflation factors (VIF) (< 3 for all variables), and false discovery rate (FDR) control was used to account for multiple testing.</p><p><strong>Results: </strong>Among the 457 participants, 54.9% were male and 60% of participants were married. Escitalopram was the most frequently prescribed single agent (12.9%), and Selective serotonin reuptake inhibitors as a class accounted for 32.1% of monotherapy prescriptions. Combination therapy was used by 26.7% of participants; typical pairs included mirtazapine + escitalopram (12.2%) and mirtazapine + fluoxetine (5.5%). The U-ASEC demonstrated good internal consistency (Cronbach's alpha = 0.78). Factor analysis identified three clusters of adverse effects: autonomic dysfunction, Central Nervous System effects, and metabolic effects. Dry mouth and insomnia were the most frequently reported adverse effects of SSRIs. Adverse effects varied by class: TCAs had higher rates of nausea/vomiting (41.3%); SNRIs were associated with a higher prevalence of urinary difficulties (32.4%); atypicals reduced dry mouth (18.8%) but increased dizziness (10.4%); and dual therapy showed more metabolic effects, including weight gain (29.5%) and increased body temperature (20.5%). Significant associations were identified for dry mouth (p = 0.0059), nausea and vomiting (p = 0.0202), problem with urination (p = 0.0248), feeling like the room is spinning (p = 0.041), and Tremor (p = 0.0382). Multivariable analysis showed TCAs increased odds of nausea (OR 3.96, 95% CI 1.72-9.03, p = 0.001), urination problems (OR 2.77, 1.10-6.63, p = 0.025), orthostatic symptoms (OR 2.59, 1.07-6.01, p = 0.030) and tremor (OR 2.66, 1.22-5.94, p = 0.015). SNRIs were associated with increased odds of urinary difficulties (OR 12.92, 1.19-284.32, p = 0.040). Atypicals reduced dry mouth (OR 0.18, 0.02-0.94, p = 0.050) but increased dizziness (OR 8.42, 1.47-48.41, p = 0.012).</p><p><strong>Conclusion: </strong>Escitalopram was the most commonly prescribed antidepressant, with dry mouth and insomnia as the most reported adverse effects. This study provides a culturally relevant tool, U-ASEC, for adverse effect monitoring, addressing critical gaps in Pakistan's clinical practices. Our findings underscore the importance of tailoring antidepressant choice to patient characteristics.</p><p><strong>Trial registration: </strong>Not applicable.</p>","PeriodicalId":7942,"journal":{"name":"Annals of General Psychiatry","volume":" ","pages":""},"PeriodicalIF":5.8000,"publicationDate":"2026-04-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13202848/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of General Psychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s12991-026-00644-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PSYCHIATRY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Antidepressant prescribing practices and Adverse-effect profiles are poorly characterised in Pakistan, highlighting the need for systematic evaluation. This study aimed to assess prescribing patterns, validate the Urdu version of the Antidepressant Side-Effect Checklist (U-ASEC), and document patient-reported adverse effects.

Methods: A cross-sectional questionnaire-based study was conducted at two psychiatry clinics in Lahore and Rawalpindi. All adult patients diagnosed with MDD according to the DSM-5-TR were invited to participate. Sampling was done through a convenient method. The Urdu-translated Antidepressant Side-Effect Checklist (U-ASEC) was developed through forward-back translation, expert panel review and pilot testing, and its psychometric properties such as internal consistency, construct validity were examined. Descriptive statistics were used to summarize demographic and clinical characteristics. Differences in adverse-effect scores across demographic and clinical groups were assessed with Kruskal-Wallis tests followed by Dunn's test with Bonferroni adjustment. Multivariable logistic regression models were fitted for each adverse-effect item to explore associations with antidepressant classes, adjusting for age, sex, tobacco use, comorbidity and duration of MDD. Multicollinearity was checked using variance inflation factors (VIF) (< 3 for all variables), and false discovery rate (FDR) control was used to account for multiple testing.

Results: Among the 457 participants, 54.9% were male and 60% of participants were married. Escitalopram was the most frequently prescribed single agent (12.9%), and Selective serotonin reuptake inhibitors as a class accounted for 32.1% of monotherapy prescriptions. Combination therapy was used by 26.7% of participants; typical pairs included mirtazapine + escitalopram (12.2%) and mirtazapine + fluoxetine (5.5%). The U-ASEC demonstrated good internal consistency (Cronbach's alpha = 0.78). Factor analysis identified three clusters of adverse effects: autonomic dysfunction, Central Nervous System effects, and metabolic effects. Dry mouth and insomnia were the most frequently reported adverse effects of SSRIs. Adverse effects varied by class: TCAs had higher rates of nausea/vomiting (41.3%); SNRIs were associated with a higher prevalence of urinary difficulties (32.4%); atypicals reduced dry mouth (18.8%) but increased dizziness (10.4%); and dual therapy showed more metabolic effects, including weight gain (29.5%) and increased body temperature (20.5%). Significant associations were identified for dry mouth (p = 0.0059), nausea and vomiting (p = 0.0202), problem with urination (p = 0.0248), feeling like the room is spinning (p = 0.041), and Tremor (p = 0.0382). Multivariable analysis showed TCAs increased odds of nausea (OR 3.96, 95% CI 1.72-9.03, p = 0.001), urination problems (OR 2.77, 1.10-6.63, p = 0.025), orthostatic symptoms (OR 2.59, 1.07-6.01, p = 0.030) and tremor (OR 2.66, 1.22-5.94, p = 0.015). SNRIs were associated with increased odds of urinary difficulties (OR 12.92, 1.19-284.32, p = 0.040). Atypicals reduced dry mouth (OR 0.18, 0.02-0.94, p = 0.050) but increased dizziness (OR 8.42, 1.47-48.41, p = 0.012).

Conclusion: Escitalopram was the most commonly prescribed antidepressant, with dry mouth and insomnia as the most reported adverse effects. This study provides a culturally relevant tool, U-ASEC, for adverse effect monitoring, addressing critical gaps in Pakistan's clinical practices. Our findings underscore the importance of tailoring antidepressant choice to patient characteristics.

Trial registration: Not applicable.

抗抑郁药处方模式和患者报告的不良反应:来自巴基斯坦的横断面研究。
背景:在巴基斯坦,抗抑郁药处方做法和不良反应概况的特征很差,这突出了系统评估的必要性。本研究旨在评估处方模式,验证乌尔都语版本的抗抑郁药副作用清单(U-ASEC),并记录患者报告的不良反应。方法:在拉合尔和拉瓦尔品第的两家精神病学诊所进行横断面问卷调查。所有根据DSM-5-TR诊断为重度抑郁症的成年患者被邀请参加。采用方便的方法进行抽样。通过前后翻译、专家小组评审和试点测试,编制了乌尔都语翻译的抗抑郁药物副作用检查表(U-ASEC),并对其内部一致性、结构效度等心理测量学特性进行了检验。描述性统计用于统计人口学和临床特征。用Kruskal-Wallis测试和Dunn测试(Bonferroni调整)评估人口统计学组和临床组的不良反应评分差异。对每个不良反应项目拟合多变量logistic回归模型,以探索与抗抑郁药物类别的关系,调整年龄、性别、烟草使用、合并症和重度抑郁症持续时间。采用方差膨胀因子(VIF)检验多重共线性(结果:457名被试中,男性占54.9%,已婚占60%)。艾司西酞普兰是最常用的单药(12.9%),选择性血清素再摄取抑制剂占单药处方的32.1%。26.7%的参与者使用联合治疗;典型的配对包括米氮平+艾司西酞普兰(12.2%)和米氮平+氟西汀(5.5%)。U-ASEC具有良好的内部一致性(Cronbach’s alpha = 0.78)。因子分析确定了三组不良反应:自主神经功能障碍、中枢神经系统影响和代谢影响。口干和失眠是ssri类药物最常见的副作用。不良反应因类别而异:TCAs有较高的恶心/呕吐率(41.3%);snri类药物与尿路困难发生率较高相关(32.4%);非典型药物减少口干(18.8%),但增加头晕(10.4%);双重治疗显示出更多的代谢作用,包括体重增加(29.5%)和体温升高(20.5%)。口干(p = 0.0059)、恶心和呕吐(p = 0.0202)、排尿困难(p = 0.0248)、感觉房间在旋转(p = 0.041)和震颤(p = 0.0382)的显著相关性被发现。多变量分析显示,TCAs增加了恶心(OR 3.96, 95% CI 1.72-9.03, p = 0.001)、排尿问题(OR 2.77, 1.10-6.63, p = 0.025)、直立症状(OR 2.59, 1.07-6.01, p = 0.030)和震颤(OR 2.66, 1.22-5.94, p = 0.015)的发生率。SNRIs与泌尿困难发生率增加相关(OR 12.92, 1.19-284.32, p = 0.040)。非典型药物减少口干(OR 0.18, 0.02-0.94, p = 0.050),但增加头晕(OR 8.42, 1.47-48.41, p = 0.012)。结论:艾司西酞普兰是最常用的抗抑郁药,口干和失眠是报告最多的不良反应。这项研究提供了一个与文化相关的工具,U-ASEC,用于不良反应监测,解决巴基斯坦临床实践中的关键差距。我们的发现强调了根据病人的特点选择抗抑郁药的重要性。试验注册:不适用。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
6.60
自引率
2.70%
发文量
43
审稿时长
>12 weeks
期刊介绍: Annals of General Psychiatry considers manuscripts on all aspects of psychiatry, including neuroscience and psychological medicine. Both basic and clinical neuroscience contributions are encouraged. Annals of General Psychiatry emphasizes a biopsychosocial approach to illness and health and strongly supports and follows the principles of evidence-based medicine. As an open access journal, Annals of General Psychiatry facilitates the worldwide distribution of high quality psychiatry and mental health research. The journal considers submissions on a wide range of topics including, but not limited to, psychopharmacology, forensic psychiatry, psychotic disorders, psychiatric genetics, and mood and anxiety disorders.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书